Akari Therapeutics plc ADS - ADR
$11.40
$1.25
(12.32%)
As on 03-Sep-2026 16:00EDT
Market cap
$21 Mln
Revenue (TTM)
$0 Mln
P/E Ratio
--
P/B Ratio
0.9
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$0 Mln
-
ROE
-1.4 %
-
ROCE
-- %
-
Industry P/E
--
-
EV/EBITDA
-0.1
-
Debt to Equity
0
-
Book Value
$--
-
EPS
$-1335.9
-
Face value
--
-
Shares outstanding
1,946,982
10 Years Aggregate
CFO
$-188.24 Mln
EBITDA
$-253.94 Mln
Net Profit
$-202.90 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Akari Therapeutics plc ADS - ADR
| -1.4 | 45.0 | -22.1 | -59.3 | -56.0 | -62.1 | -47.6 |
|
BSE Sensex
| -10.1 | -2.5 | 2.0 | -5.0 | 5.2 | 5.7 | 10.3 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Akari Therapeutics plc ADS - ADR
| -76.3 | -60.6 | -66.8 | -68.7 | -18.9 | 5.7 | 11.5 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Akari Therapeutics plc ADS - ADR
|
11.4 | 20.8 | 0.0 | -31.0 | -- | -132 | -- | 0.9 |
| 86.5 | 11,993.9 | 669.5 | -320.0 | -0.8 | -71.1 | -- | 26.9 | |
| 271.1 | 16,261.1 | 1,054.4 | 755.9 | 5.7 | -- | 19 | 9.8 | |
| 74.0 | 10,022.2 | 71.0 | -894.0 | -1,175.8 | -- | -- | 60.3 | |
| 59.1 | 13,491.7 | 2,435.9 | 860.6 | 31.0 | 43 | 17.4 | 7.4 | |
| 110.8 | 11,957.0 | 1,663.7 | 413.6 | 36.3 | 430 | 30.9 | 84.5 | |
| 371.5 | 10,402.8 | 440.5 | 241.5 | 33.4 | 18.7 | 44.1 | 7.8 | |
| 542.6 | 12,332.1 | 1,283.9 | -325.1 | -19.0 | -57.7 | -- | 24.0 | |
| 593.4 | 16,765.1 | 2,782.3 | 491.5 | 21.1 | 110.1 | 35.2 | 39.3 | |
| 355.2 | 9,625.4 | 0.0 | -339.1 | -- | -30.6 | -- | 7.6 |
Shareholding Pattern
View DetailsAbout Akari Therapeutics plc ADS - ADR
Akari Therapeutics, Plc, an oncology company, develops antibody-drug conjugates (ADC) for cancer-killing toxins. Its lead payload is PH1 to disrupt the function of spliceosomes and to trigger an immune response that leads to additional cancer cell... killing. The company's lead product candidate is AKTX-101, a preclinical stage trop2-targeting ADC that combines PH1 with the trop2 antibody to treat solid tumor cancer types, including lung, breast, bladder, head and neck, gastric, pancreatic, colon, prostate, and others. Its payloads include PH1 is a novel payload that is a spliceosome modulator designed to disrupt RNA splicing within cancer cells. The company also develops AKTX-102, a novel bispecific ADC that utilizes PH1 as its payload to treat various solid tumor cancers. Akari Therapeutics, Plc is headquartered in Tampa, Florida. Read more
-
President, CEO & Director
Ms. Rachelle Suzanne Jacques
-
Interim President, CEO & Director
Dr. Samir Rashmikant Patel M.D.
-
Headquarters
Tampa, FL
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Akari Therapeutics plc ADS - ADR
What is the current share price of Akari Therapeutics plc ADS - ADR Today?
The share price of Akari Therapeutics plc ADS - ADR is $11.40 (NASDAQ) as of 03-Sep-2026 16:00 EDT. Akari Therapeutics plc ADS - ADR has given a return of -55.97% in the last 3 years.
What is the current PB & PE ratio of Akari Therapeutics plc ADS - ADR?
Since, TTM earnings of Akari Therapeutics plc ADS - ADR is negative, P/E ratio is not available.
The P/B ratio of Akari Therapeutics plc ADS - ADR is 0.94 times as on 28-Aug-2026, a 82 discount to its peers’ median range of 5.18 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
2025 |
0.00 |
0.00 |
2024 |
-3,278.66 |
2,919.07 |
2023 |
0.00 |
-0.03 |
2022 |
0.00 |
0.00 |
2021 |
0.00 |
0.00 |
What is the 52 Week High and Low of Akari Therapeutics plc ADS - ADR?
The 52-week high and low of Akari Therapeutics plc ADS - ADR are Rs 49.60 and Rs 3.02 as of 04-Sep-2026.
What is the market cap of Akari Therapeutics plc ADS - ADR?
Akari Therapeutics plc ADS - ADR has a market capitalisation of $ 21 Mln as on 28-Aug-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in Akari Therapeutics plc ADS - ADR?
Before investing in Akari Therapeutics plc ADS - ADR, assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.